Proton pump inhibitors for the treatment of laryngopharyngeal reflux disease

Abstract

Background: Laryngopharyngeal Reflux disease refers to abnormal reflux of gastric contents through the esophagus into the throat, which irritates and damages the pharyngeal mucosa, and causes corresponding symptoms. Proton Pump Inhibitors are an important class of gastric acid secretion inhibitors after H2 receptor blockers, which can be used clinically to treat peptic ulcer, abnormal gastric acid secretion and other related diseases. The common clinical drugs include omeprazole, lansoprazole, rabeprazole and so on. Clinical practice has shown that Proton Pump Inhibitors have a good therapeutic effect on Laryngopharyngeal Reflux disease, but evidence of evidence-based medicine is lacking. The purpose of this protocol is to systematically evaluate the efficacy and safety of Proton Pump Inhibitors in the treatment of Laryngopharyngeal Reflux disease and to improve the evidence-based basis for the clinical application of Proton Pump Inhibitors in the treatment of Laryngopharyngeal Reflux disease. Methods: English computer retrieval database (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese computer retrieval database (Wanfang Database, VIP Information Chinese Journal Service Platform, Chinese Biomedical Database) . In addition, Baidu Scholar and Google Scholar were manually searched for randomized controlled clinical studies on the treatment of laryngeal reflux disease with Proton Pump Inhibitors from the establishment of the database to July 2020. Two researchers independently extracted and evaluated the data of the included studies, and meta-analysis was conducted on the included literatures with RevMan5.3 software without language restrictions. Results: In this study, the efficacy and safety of Proton Pump Inhibitors in the treatment of Laryngopharyngeal Reflux disease are evaluated by the overall response rate, clinical symptom remission rate and other indicators. Conclusions: This study will provide reliable evidence-based evidence for the clinical application of Proton Pump Inhibitors in the treatment of Laryngopharyngeal Reflux disease. OSF Registration number: DOI 10.17605 / OSF.IO / NY6SC

Teeth Damage Due to Extraesophageal Reflux

“…Přesto je jejich na mimojícnové projevy menší v porovnání s léčbou refluxní nemoci jícnu. IPP jenom snižují kyselost, nebrání však výrazněji v refluxu [11,12].…”

Meta-analysis of Proton Pump Inhibitors in the Treatment of Pharyngeal Reflux Disease

“…PPIs are commonly used in the clinical empirical treatment of laryngopharyngeal reflux diseases. Inhibiting H + -K+ -ATPase on gastric wall cells, decreasing gastric acid output, decreasing pepsin activity, and blocking the inflammatory response are the treatment methods used to lessen the direct throat damage [ 10 ]. However, the effectiveness of proton pump inhibitors in the treatment of laryngopharyngeal reflux disease has long been controversial.…”

Association between Proton Pump Inhibitors and Hearing Impairment: A Nested Case-Control Study

“…Proton pump inhibitors (PPIs) have been widely used for the treatment of several acid-related disorders, such as gastroesophageal reflux disease (GERD), gastric ulcer, duodenal ulcer, erosive esophagitis, and laryngeal reflux diseases [1,2]. PPIs act as antacids by irreversibly inhibiting H+/K+ ATPase [3].…”